Journal
AMERICAN JOURNAL OF PSYCHIATRY
Volume 158, Issue 10, Pages 1725-1727Publisher
AMER PSYCHIATRIC PRESS, INC
DOI: 10.1176/appi.ajp.158.10.1725
Keywords
-
Categories
Funding
- NCRR NIH HHS [RR-00827] Funding Source: Medline
Ask authors/readers for more resources
Objective: The effectiveness of pindolol as an adjunctive treatment to boost response to selective serotonin reuptake inhibitors (SSRls) in patients with generalized social phobia was tested. Method: A double-blind, placebo-controlled, crossover design was used to compare addition of 5 mg of pindolol t.i.d. or placebo for 4 weeks to a steady paroxetine dose. Subjects were 14 patients with generalized social phobia who were less than very much improved on the Clinical Global Impression scale after at least 10 weeks of treatment with a maximally tolerated dose of paroxetine. Changes on the Liebowitz Social Anxiety Scale and the Social Phobia inventory scores were compared across the two crossover periods. Results: Pindolol was not significantly superior to placebo for augmenting the effects of paroxetine on social anxiety symptoms. None of the 14 subjects was deemed a responder to the pindolol arm of the crossover. Conclusions: Pindolol was no more effective than placebo in augmenting the effects of SSRI treatment for generalized social phobia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available